Abstract:At clinically-relevant doses, selective JAK1 and JAK2 inhibitors are well-tolerated and suppress IFNg-mediated STAT1 phosphorylation. Selective JAK1 versus JAK2 inhibition differentially impacts the clinical and laboratory manifestations of disease in mouse models of HLH. Hemophagocytic lymphohistiocytosis (HLH) comprises a severe hyperinflammatory phenotype driven by the overproduction of cytokines, many of which signal via the JAK/STAT pathway. Indeed, the JAK1/2 inhibitor ruxolitinib has demonstrated efficacy in pre-clinical studies and early-phase clinical trials in HLH. Nevertheless, concerns remain for ruxolitinib-induced cytopenias, which are postulated to result from the blockade of JAK2-dependent hematopoietic growth factors. To explore the therapeutic effects of selective JAK inhibition in mouse models of HLH, we carried out studies incorporating the JAK1 inhibitor itacitinib, the JAK2 inhibitor fedratinib and the JAK1/2 inhibitor ruxolitinib. All three drugs were well-tolerated and at the doses tested, they suppressed interferon-gamma (IFNg)-induced STAT1 phosphorylation in vitro and in vivo. Itacitinib, but not fedratinib, significantly improved survival and clinical scores in CpG-induced secondary HLH. Conversely, in primary HLH, where perforin-deficient (Prf1-/-) mice are infected with lymphocytic choriomeningitis virus (LCMV), itacitinib and fedratinib performed suboptimally. Ruxolitinib demonstrated excellent clinical efficacy in both HLH models. RNA-sequencing of splenocytes from LCMV-infected Prf1-/- mice revealed that itacitinib targeted inflammatory and metabolic pathway genes in CD8 T cells, while fedratinib targeted genes regulating cell proliferation and metabolism. In monocytes, neither drug conferred major transcriptional impacts. Consistent with its superior clinical effects, ruxolitinib exerted the greatest transcriptional changes in CD8 T cells and monocytes, targeting more genes across several biologic pathways, most notably JAK-dependent pro-inflammatory signaling. We conclude that JAK1 inhibition is sufficient to curtail CpG-induced disease, but combined inhibition of JAK1 and JAK2 is needed to best control LCMV-induced immunopathology.

Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome.

Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in rat.

Expression of JAKs/STATs Pathway Molecules in Rat Model of Rapid Focal Segmental Glomerulosclerosis

Pharmacological Inhibition of STAT6 Ameliorates Myeloid Fibroblast Activation and Alternative Macrophage Polarization in Renal Fibrosis

JAK/STAT signal in renal interstitial fibrosis

STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model

Therapeutic JAK1 Inhibition Reverses Lupus Nephritis in a Mouse Model and Demonstrates Transcriptional Changes Consistent With Human Disease

Renoprotective Effect of the Recombinant Anti-IL-6R Fusion Proteins by Inhibiting JAK2/STAT3 Signaling Pathway in Diabetic Nephropathy

Pharmacologic Inhibiting STAT3 Delays the Progression of Kidney Fibrosis in Hyperuricemia-Induced Chronic Kidney Disease.

JAK/STAT Signaling Controls the Fate of CD8+CD103+ Tissue-Resident Memory T Cell in Lupus Nephritis

Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats

Expression of suppressor of cytokine signaling 3 during the course of mouse nephritis

Effect of matrine on STAT3 signaling molecule in adriamycin-induced glomerular sclerosis rat

Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?

Knockdown of Stat3 Activity in Vivo Prevents Diabetic Glomerulopathy

STAT1 aggravates kidney injury by NOD-like receptor (NLRP3) signaling in MRL-lpr mice

Treatment with a JAK1/2 inhibitor ameliorates murine autoimmune cholangitis induced by IFN overexpression

Inhibition of STAT3 Acetylation is Associated with Attenuated Renal Fibrosis in the Obstructed Kidney

Therapeutic Efficacy of Suppressing the JAK/STAT Pathway in Multiple Models of Experimental Autoimmune Encephalomyelitis

Ac-SDKP ameliorates the progression of lupus nephritis in MRL/lpr mice.

Differential Effects of JAK1 vs. JAK2 Inhibition in Mouse Models of Hemophagocytic Lymphohistiocytosis